ReviewCurrent pharmaceutical biotechnology2010
Open access high throughput drug discovery in the public domain: a Mount Everest in the making.
Review in Current pharmaceutical biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Big Data and Artificial Intelligence in Cancer Drug Discovery: Promise, Challenges, and Emerging Opportunities.Cancers · 2026Review
- In Vivo Acute Toxicity Studies of Novel Anti-Melanoma Compounds Downregulators of hnRNPH1/H2.Biomolecules · 2023Article
- Evolving scenario of big data and Artificial Intelligence (AI) in drug discovery.Molecular diversity · 2021Article
- Chemical Screening of Nuclear Receptor Modulators.International journal of molecular sciences · 2020Review
- Natural Products as Modulators of Sirtuins.Molecules (Basel, Switzerland) · 2020Review
- Prediction of drug combination effects with a minimal set of experiments.Nature machine intelligence · 2019Article
- Quality Control of Quantitative High Throughput Screening Data.Frontiers in genetics · 2019Article
- Linguistic measures of chemical diversity and the "keywords" of molecular collections.Scientific reports · 2018Article
- Early Probe and Drug Discovery in Academia: A Minireview.High-throughput · 2018Review
- NMR-Fragment Based Virtual Screening: A Brief Overview.Molecules (Basel, Switzerland) · 2018Review
- Data Mining and Computational Modeling of High-Throughput Screening Datasets.Methods in molecular biology (Clifton, N.J.) · 2018Article
- PubChem BioAssay: A Decade's Development toward Open High-Throughput Screening Data Sharing.SLAS discovery : advancing life sciences R & D · 2017Article
- Scaffold Diversity of Fungal Metabolites.Frontiers in pharmacology · 2017Article
- Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Using cultured endothelial cells to study endothelial barrier dysfunction: Challenges and opportunities.American journal of physiology. Lung cellular and molecular physiology · 2016Review
- Consensus Diversity Plots: a global diversity analysis of chemical libraries.Journal of cheminformatics · 2016Article
- DNA-Encoded Solid-Phase Synthesis: Encoding Language Design and Complex Oligomer Library Synthesis.ACS combinatorial science · 2015Article
- Computational prediction and validation of an expert's evaluation of chemical probes.Journal of chemical information and modeling · 2014Article
- Metadata Standard and Data Exchange Specifications to Describe, Model, and Integrate Complex and Diverse High-Throughput Screening Data from the Library of Integrated Network-based Cellular Signatures (LINCS).Journal of biomolecular screening · 2014Article
- Overcoming scientific and structural bottlenecks in antibacterial discovery and development.Upsala journal of medical sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
High throughput screening (HTS) facilitates screening large numbers of compounds against a biochemical target of interest using validated biological or biophysical assays. In recent years, a significant number of drugs in clinical trails originated from HTS campaigns, validating HTS as a bona fide mechanism for hit finding. In the current drug discovery landscape, the pharmaceutical industry is embracing open innovation strategies with academia to maximize their research capabilities and to feed their drug discovery pipeline. The goals of academic research have therefore expanded from target identification and validation to probe discovery, chemical genomics, and compound library screening. This trend is reflected in the emergence of HTS centers in the public domain over the past decade, ranging in size from modestly equipped academic screening centers to well endowed Molecular Libraries Probe Centers Network (MLPCN) centers funded by the NIH Roadmap initiative. These centers facilitate a comprehensive approach to probe discovery in academia and utilize both classical and cutting-edge assay technologies for executing primary and secondary screening campaigns. The various facets of academic HTS centers as well as their implications on technology transfer and drug discovery are discussed, and a roadmap for successful drug discovery in the public domain is presented. New lead discovery against therapeutic targets, especially those involving the rare and neglected diseases, is indeed a Mount Everestonian size task, and requires diligent implementation of pharmaceutical industry's best practices for a successful outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.